140 related articles for article (PubMed ID: 15277926)
1. Retigabine stimulates human KCNQ2/Q3 channels in the presence of bupivacaine.
Punke MA; Friederich P
Anesthesiology; 2004 Aug; 101(2):430-8. PubMed ID: 15277926
[TBL] [Abstract][Full Text] [Related]
2. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels.
Wickenden AD; Yu W; Zou A; Jegla T; Wagoner PK
Mol Pharmacol; 2000 Sep; 58(3):591-600. PubMed ID: 10953053
[TBL] [Abstract][Full Text] [Related]
3. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine.
Main MJ; Cryan JE; Dupere JR; Cox B; Clare JJ; Burbidge SA
Mol Pharmacol; 2000 Aug; 58(2):253-62. PubMed ID: 10908292
[TBL] [Abstract][Full Text] [Related]
4. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine.
Tatulian L; Delmas P; Abogadie FC; Brown DA
J Neurosci; 2001 Aug; 21(15):5535-45. PubMed ID: 11466425
[TBL] [Abstract][Full Text] [Related]
5. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits.
Rundfeldt C; Netzer R
Neurosci Lett; 2000 Mar; 282(1-2):73-6. PubMed ID: 10713399
[TBL] [Abstract][Full Text] [Related]
6. Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells.
Wickenden AD; Zou A; Wagoner PK; Jegla T
Br J Pharmacol; 2001 Jan; 132(2):381-4. PubMed ID: 11159685
[TBL] [Abstract][Full Text] [Related]
7. Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties.
Peretz A; Degani N; Nachman R; Uziyel Y; Gibor G; Shabat D; Attali B
Mol Pharmacol; 2005 Apr; 67(4):1053-66. PubMed ID: 15598972
[TBL] [Abstract][Full Text] [Related]
8. Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells.
Tatulian L; Brown DA
J Physiol; 2003 May; 549(Pt 1):57-63. PubMed ID: 12702739
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of retigabine against levobupivacaine-induced central nervous system toxicity: a prospective, randomized animal study.
Cheng Y; Li H; Li J; Chen Y; Duan R; Yuan J; Zhao S
J Anesth; 2016 Feb; 30(1):109-15. PubMed ID: 26302692
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a retigabine derivative that inhibits KCNQ2 potassium channels.
Hu HN; Zhou PZ; Chen F; Li M; Nan FJ; Gao ZB
Acta Pharmacol Sin; 2013 Oct; 34(10):1359-66. PubMed ID: 23933653
[TBL] [Abstract][Full Text] [Related]
11. N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator.
Wickenden AD; Krajewski JL; London B; Wagoner PK; Wilson WA; Clark S; Roeloffs R; McNaughton-Smith G; Rigdon GC
Mol Pharmacol; 2008 Mar; 73(3):977-86. PubMed ID: 18089837
[TBL] [Abstract][Full Text] [Related]
12. M channels containing KCNQ2 subunits modulate norepinephrine, aspartate, and GABA release from hippocampal nerve terminals.
Martire M; Castaldo P; D'Amico M; Preziosi P; Annunziato L; Taglialatela M
J Neurosci; 2004 Jan; 24(3):592-7. PubMed ID: 14736843
[TBL] [Abstract][Full Text] [Related]
13. Sequence determinants of subtype-specific actions of KCNQ channel openers.
Wang AW; Yang R; Kurata HT
J Physiol; 2017 Feb; 595(3):663-676. PubMed ID: 27506413
[TBL] [Abstract][Full Text] [Related]
14. KCNQ4 channel activation by BMS-204352 and retigabine.
Schrøder RL; Jespersen T; Christophersen P; Strøbaek D; Jensen BS; Olesen SP
Neuropharmacology; 2001 Jun; 40(7):888-98. PubMed ID: 11378159
[TBL] [Abstract][Full Text] [Related]
15. Involvement of KCNQ2 subunits in [3H]dopamine release triggered by depolarization and pre-synaptic muscarinic receptor activation from rat striatal synaptosomes.
Martire M; D'Amico M; Panza E; Miceli F; Viggiano D; Lavergata F; Iannotti FA; Barrese V; Preziosi P; Annunziato L; Taglialatela M
J Neurochem; 2007 Jul; 102(1):179-93. PubMed ID: 17437547
[TBL] [Abstract][Full Text] [Related]
16. Personalized treatment with retigabine for pharmacoresistant epilepsy arising from a pathogenic variant in the KCNQ2 selectivity filter.
Nissenkorn A; Kornilov P; Peretz A; Blumkin L; Heimer G; Ben-Zeev B; Attali B
Epileptic Disord; 2021 Oct; 23(5):695-705. PubMed ID: 34519644
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human TREK-1 channels by bupivacaine.
Punke MA; Licher T; Pongs O; Friederich P
Anesth Analg; 2003 Jun; 96(6):1665-1673. PubMed ID: 12760993
[TBL] [Abstract][Full Text] [Related]
18. Amitriptyline is a potent blocker of human Kv1.1 and Kv7.2/7.3 channels.
Punke MA; Friederich P
Anesth Analg; 2007 May; 104(5):1256-64, tables of contents. PubMed ID: 17456683
[TBL] [Abstract][Full Text] [Related]
19. Local anesthetic interaction with human ether-a-go-go-related gene (HERG) channels: role of aromatic amino acids Y652 and F656.
Siebrands CC; Schmitt N; Friederich P
Anesthesiology; 2005 Jul; 103(1):102-12. PubMed ID: 15983462
[TBL] [Abstract][Full Text] [Related]
20. KCNQ3 is the principal target of retigabine in CA1 and subicular excitatory neurons.
Varghese N; Lauritano A; Taglialatela M; Tzingounis AV
J Neurophysiol; 2021 Apr; 125(4):1440-1449. PubMed ID: 33729829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
